Signs and Symptoms


Signs and symptoms of Fabry disease are multi-systemic and increase in number and severity over time. Lack of sufficient α-galactosidase (α-GAL) activity leads to progressive accumulation of the glycosphingolipids globotriaosylceramide (denoted GL3 or Gb3) and globotriaosylsphingosine (lyso-GL3 or lyso-Gb3) within lysosomes in a variety of cell types, including vascular endothelium, podocytes, arterial smooth muscle cells, and cardiomyocytes.11,12


To read more about Fabry disease pathophysiology, click here.

1. Wilcox WR, et al. Mol Genet Metab. 2008;93(2):112–128. 2. NIH US National Library of Medicine Accessed Mar 2018. 3. Weidemann F, et al. Ann Rev Med. 2011;62:59–67. 4. Desnick RJ, et al. Ann Intern Med. 2003;138(4):338–346. 5. Niemann M, et al. JACC Cardiovasc Imaging. 2011;4(6):592–601. 6. Veloso VSP, et al. Nephron. 2018;138(2):147–156. b Ortiz A, et al. Mol Genet Metab. 2018;123(4):416–427. 8. MacDermot KD, et al. J Med Genet. 2001;38(11):750–760. 9. MacDermot KD, et al. J Med Genet. 2001;38(11):769–775. 10. Park JY, et al. Exp Mol Med. 2009;41(1):1–7. 11. Germain DP. Orphanet J Rare Dis. 2010;5:30. 12. Zarate YA, Hopkin RJ. Lancet. 2008;372(9647):1427–1435.

Next in Fabry Disease